Dangerous Drug Interactions
Dangerous Drug Interactions
Authors:
Larissa I. Velez, MD, FACEP, Associate Professor of Emergency Medicine, Medical Toxicologist, University of Texas Southwestern Medical Center, Dallas.
Sing-Yi Feng, MD, Assistant Professor of Pediatrics, Medical Toxicologist, University of Texas Southwestern Medical Center, Dallas.
Collin S. Goto, MD, Associate Professor of Pediatrics, Medical Toxicologist, University of Texas Southwestern Medical Center, Dallas.
Fernando L. Benitez, MD, Associate Professor of Emergency Medicine, University of Texas Southwestern Medical Center, Dallas.
Peer Reviewer:
Frank LoVecchio, DO, Emergency Medicine Department, Maricopa Medical Center, Phoenix, AZ.
My emergency department (ED) has had an electronic medical record for the past two years. Part of that record includes a medication list that is created from past encounters and updated by the triage nurse. Because it is electronic and prints out nicely in the triage summary, it has the appearance of truth. My experience with the list is likely similar to some of yours: Patients are often taking medications not on the list and are not currently taking those that are. So, my caution to the residents before prescribing any new medication is to ask patients if they are currently taking any of the medications on the list or taking anything not listed. That way, we can minimize the potential for some for the dangerous drug interactions discussed in this review.
J. Stephan Stapczynski, MD. Editor
Background
Drug interactions have become more common because of the increased use of multiple prescription drugs, advancing age of the population, and the complexities of modern health care. For example, the average American adult who is 55 years old or older uses 6 to 9 medications daily.1 The high-profile deaths of artists and celebrities due to the use of medications and drugs have brought incredible attention to this subject by both the media and the public. In addition, a 1999 Institute of Medicine report highlighted drug reactions (including interactions) as one of the reasons for preventable mortality in the United States.
Interactions are defined as situations in which a substance affects the activity of a drug. The drug's effects can be either increased or decreased, or a new effect can be produced that neither the substance nor drug previously exhibited.2 Although most drug interactions are between two or more drugs, other important drug interactions can involve drugs with herbs as well as drugs with foods.2
In general, drug interactions must be avoided because the effect can have an unexpected, unpredictable, or adverse outcome. However, certain drug interactions are produced intentionally because they can be clinically beneficial. These clinically useful interactions are known as pharmacologic augmentations or pharmacologic synergisms. One historic example of pharmacologic augmentation was the use of probenecid with penicillin. Initially, penicillin was very difficult to manufacture. Probenecid was added to penicillin, as it helped delay the renal excretion of penicillin, thereby prolonging its clinical effect.2 A modern example is the use of carbidopa with levodopa in the management of Parkinson's disease. Levodopa, when used individually, is metabolized in the peripheral tissues. This decreases the availability of levodopa in the brain and increases the risk of adverse effects. Carbidopa inhibits the peripheral metabolism of levodopa, allowing more unmetabolized levodopa to reach the brain, therefore increasing clinical efficacy and reducing the risk of peripheral side effects.
Epidemiology
Drug interactions are a leading cause of morbidity and mortality in the United States because the rates of per-capita prescription medication use have considerably increased in the past few decades, as have the rates of use of over-the-counter medications and supplements.3 In a medication survey of residents of a senior community, 4% of those older than 55 years of age are taking a medicine that puts them at risk for a drug interaction, with about half of those involving non-prescription drugs (over-the-counter medications, supplements, or herbs).1 Because of the common use of prescription, over-the-counter drugs and herbals, drug errors and adverse drug effects are the most common cause of iatrogenic illness in the United States.4
Drug interactions frequently occur in high acuity areas of the hospital, such as the intensive care unit (ICU) and the ED. In a recent study of more than 400 ICU patients, 225 patients had a potential drug interaction. The most commonly reported drug interactions included anticoagulation problems, QT prolongation, and p450 inhibition. Of the reported drug interactions in the study, 5-9% were considered major or contraindicated drug combinations.5 In the ED, a study found that patients are at a high risk for a drug interaction if they are younger than 50 years of age and taking more than three medications daily or if they are older than 50 years of age and taking more than two daily medicines.6
Drug interactions result in excess hospitalizations. In one study, drug-drug interactions were responsible for 0.57% of hospitalizations, but this number rose to 4.8% in the elderly.7 The drugs most commonly involved in this study were nonsteroidal anti-inflammatory drugs (NSAIDs) and cardiovascular drugs. The most common reasons for admission due to these drug interactions were gastrointestinal bleeding (GI) bleeding, hypertension, hypotension, and cardiac rhythm disturbances.7
Patients in the hospital can also be discharged with multiple drugs that can cause significant interactions. A review of hospitalized patients' medication profiles upon hospital discharge showed that 62.5% of patients had been discharged with a potential drug interaction. Of these, 38% were of moderate severity, and 2% were considered of major severity.8
Unintentional poisoning caused 20,000 deaths in 2004, making it the second leading cause of accidental death in the United States.9 Therefore, it is of no surprise that drug-related morbidity and mortality have been estimated to cost more than $130 billion per year in the United States alone.4
Demographics
The elderly are at risk for developing drug interactions due to their overall increased risk of developing illness and, therefore, increasing their use of prescription and over-the-counter medications. As mentioned previously, the elderly are more likely to take multiple medications. Although individuals older than 65 years of age represent only 13% of the total U.S. population, it has been estimated that they consume nearly one-third of all medications in the United States.10 This increased use of medications in the elderly, combined with their decreased metabolism and impaired clearance of medications, greatly increases their risk for developing drug interactions.11-13
Critically ill patients are also at risk for developing drug interactions due to the fact that they are exposed to a large number of drugs during their illness. In addition, critically ill patients are likely to have organ dysfunction resulting in impaired metabolism and clearance of drugs. In one ICU study from Europe published in 1997, 70 patients were evaluated for possible drug interactions. More than 100 drug interactions were found among 44.3% of those patients (an average of 1.5 interactions per patient). On average, these ICU patients were receiving more than 14 drugs per patient, with digoxin causing the most interactions.14
Other populations at risk for developing drug interactions include psychiatric patients; patients taking high doses or multiple medications due to resistant medical conditions; poly-drug misusers and abusers; and patients in undeveloped countries who self-medicate with prescription medications easily obtained over-the-counter.11 Patients who have low albumin levels from chronic lung disease, alcoholism, or malnourishment are also at risk of developing significant drug interactions due to altered protein binding.15
Pathophysiology Mechanisms of Drug Interactions
Drug interactions can occur at any stage during or after drug administration, and even prior to administration. In general, following administration, there are two major types of interactions: pharmacokinetic interactions (how the body interacts with a drug, usually related to absorption, distribution, metabolism, and elimination); and pharmacodynamic interactions (how the drug interacts with the body, usually related to receptor-mediated physiological effects). Table 1 summarizes some of these interactions.2
Table 1: Mechanisms of Drug Interactions
|
Interaction Type |
Examples of Drug Interactions |
|
Prior to IV administration |
|
|
Prior to intestinal absorption |
|
|
During intestinal absorption |
|
|
Protein binding |
|
|
Interactions at site of metabolism |
|
|
Interactions at site of secretion (renal) |
|
|
Pharmacodynamic interactions |
|
Drug metabolism is defined as the biochemical modification of drugs by enzymatic processes. Its purpose is to convert drugs to a more water-soluble form so they can then be renally excreted. Drug metabolism is divided into two phases:
Phase 1 (also known as non-synthetic reactions) involves several different reactions, including oxidation, reduction, hydrolysis, cyclization and decyclization, addition of oxygen, or removal of hydrogen from a drug. This phase usually is achieved in the liver utilizing the cytochrome P450 (CYP450) enzymes.
Phase 2 metabolism (also known as the conjugation reactions) involves several mechanisms, including methylation, sulfation, acetylation, and glucuronidation. These reactions make the Phase 2 metabolized drug more water-soluble and usually also inactivate the drug.
The CYP450 enzymes are the major enzymes that play a vital role in the metabolism of drugs. Greater than 75% of a drug's metabolism is accomplished by the CYP450 enzymes.16 The resultant metabolites can be the active form of a drug, an inactive form, or substances that can be more or less potent than the parent compound.11 Many drugs and other substances, including foods and herbs, can increase (induce) or decrease (inhibit) the activity of CYP450. These changes in enzyme activity result in drug interactions due to altered metabolism and clearance of many drugs.16
There are many CYP450 isoenzymes, but a few are very relevant in clinical practice: CYP3A4 is induced by many drugs, such as carbamazepine, phenytoin, phenobarbital, rifampicin, and St. John's wort. This induction will augment drug metabolism and, therefore, decrease another drug's efficacy.11,17 However, CYP450 inhibition (or two drugs competing for the same isoenzyme), leading to increased drug levels, is probably most important in drug toxicity and interactions.11 For example, CYP2C9 is involved in the metabolism of warfarin. Alterations in the activity of this enzyme can result in increased anticoagulation.
Relevant Drug Interactions for the ED Physician
Warfarin Interactions. Drug interactions with warfarin are common and they place the patient at risk for major bleeding or thrombotic complications.
Drug interactions with warfarin can be either pharmacokinetic or pharmacodynamic in nature. Pharmacokinetic drug interactions are usually related to the metabolism of warfarin. Warfarin contains the isomers R and S. The S isomer is more potent and is metabolized by CYP 2C9, while the less potent R isomer is metabolized by CYP 1A2 and 3A4.20 Drugs that inhibit CYP 2C9, such as trimethoprim/sulfamethoxazole, can be expected to have a significant effect on the international normalized ratio (INR).21 Avoid these medications in patients taking warfarin or closely monitor the INR.4 (See Table 2.) Drugs have less impact on the R isomer due to its metabolism with multiple enzymes and decreased biological activity.22,23 Drugs that induce CYP450 enzymes, especially 2C9, can reduce the effect of warfarin and necessitate higher warfarin doses during treatment. Rifampin is the most common offender.4,22
Table 2: Selected Drug Interactions with Warfarin
|
Increased Effect of Warfarin (Elevated INR) |
Decreased Effect of Warfarin (Low INR) |
|
Amiodarone Azole antifungals (fluconazole) Cephalosporins Cimetidine Ethanol Fluvastatin HMG-CoA reductase inhibitors (Lovastatin) Isoniazid Macrolides (clarithromycin, erythromycin) Metronidazole NSAIDs, acetaminophen, aspirin Quinolones (ciprofloxacin) Tricyclic antidepressants |
Barbiturates Carbamazepine Cholestyramine Cigarette smoking Corticosteroids Oral contraceptives Phenytoin Primidone Rifampin St. John's wort Vitamin K |
Pharmacodynamic interactions with warfarin can also influence the safety and efficacy of anticoagulation therapy. These interactions are not as numerous as the pharmacokinetic interactions. The most common interaction with warfarin is the concomitant use of antiplatelet agents such as prescription and non-prescription NSAIDs and clopidogrel. These agents can increase bleeding risk and severity without affecting the INR. The platelet dysfunction caused by aspirin increases the risk of severe bleeding.24 Aspirin with warfarin was found to increase the risk of bleeding compared to warfarin alone by doubling the risk of intracranial hemorrhage (~1.5% per year).25 Certain herbals, such as garlic and dong quai, may also have antiplatelet effects, but these interactions are less predictable and the evidence for them is not well established.
Other forms of pharmacodynamic interactions can also affect the INR. Levothyroxine increases the catabolism of clotting factors, and vitamin K-containing foods (i.e., green leafy vegetables) increase the production of clotting factors, thereby causing INR depression.26 Even acetaminophen has been associated with higher INRs in patients taking warfarin when doses greater than 1.5 grams per day are used.27
Angiotensin-Converting Enzyme (ACE) Inhibitor Interactions. ACE inhibitors decrease the production of aldosterone, resulting in decreased potassium excretion in the distal nephron. Significant hyperkalemia usually does not occur in patients with normal renal function who are not taking other medications that cause potassium retention. However, life-threatening hyperkalemia may result in patients taking ACE inhibitor therapy when potassium homeostasis is disturbed by increased potassium intake, decreased potassium excretion, or abnormal cellular uptake. Severe cases usually involve elderly patients with precipitating factors of dehydration, renal insufficiency, and heart failure.
Notable drug interactions with ACE inhibitors that result in hyperkalemia due to decreased potassium excretion include potassium-sparing diuretics (such as amiloride, spironolactone, and triamterene), NSAIDs, trimethoprim, and cyclosporine.4 Hyperkalemia due to increased potassium intake may occur with potassium supplements or penicillin G potassium, while hyperkalemia due to abnormal cellular uptake and distribution of potassium may result from interactions with beta-adrenergic blockers, digoxin, or succinylcholine.
Digoxin Interactions. Digoxin has a narrow therapeutic index and is excreted by the kidneys, allowing several drug interactions and clinical conditions to easily alter the clinical efficacy of digoxin or result in toxicity. Dehydration, renal insufficiency, electrolyte abnormalities, acid-base disturbances, and congestive heart failure all increase the susceptibility to toxicity from digoxin-related drug interactions. Table 3 summarizes the most important drug interactions with digoxin.
Table 3: Selected Drug Interactions with Digoxin
|
Effect |
Drugs |
|
Increased serum levels |
Amiodarone Benzodiazepines Cyclosporine Itraconazole Indomethacin Macrolides Omeprazole Propafenone Quinidine Tetracyclines Verapamil |
|
Decreased serum levels |
Albuterol Aminoglycosides (oral) Aluminum/magnesium antacids Activated charcoal Cholestyramine Rifampin St. John's wort Sulfasalazine |
|
Enhanced pharmacodynamic effects |
Beta-blockers Calcium channel blockers Cyclosporine Diuretics Sympathomimetics |
|
Antagonize pharmacodynamic effects |
Thyroid hormone |
Interactions that Result in QT Interval Prolongation. Many different medications cause prolongation of the QT interval of the electrocardiogram, increasing the risk of ventricular arrhythmias, especially torsades de pointes (TDP) and sudden cardiac death.28,29 The risk of such adverse effects is dramatically increased when QT interval-prolonging medications are taken in combination, especially if the patient has underlying conditions such as bradycardia or hypokalemia that also predispose to development of TDP. Historically, a number of drugs have been withdrawn from the U.S. market due to these concerns, including astemizole, cisapride, and terfenadine.4,29 Notable classes of medications that prolong the QT interval include certain antiarrhythmics, antidepressants, antihistamines, antimicrobials, antipsychotics, azole antifungals, and protease inhibitors.18,28-34 (See Table 4.)
Table 4: Drugs that Prolong the QT Interval
|
Drug Family |
Drug Family |
|
Antiarrhythmics 1A: disopyramide, procainamide, quinidine 1C: flecainide, encainide III: amiodarone, ibutilide, sotalol |
Azole antifungals (ketoconazole, miconazole, itraconazole) |
|
Antidepressants (tricyclics, SSRIs, lithium) |
Calcium channel blockers (diltiazem, verapamil) |
|
Antihistamines (astemizole, diphenhydramine, hydroxyzine, terfenadine) |
Protease inhibitors |
|
Antimicrobials (amantadine, quinine, chloroquine, ciprofloxacin, macrolides, pentamidine) |
Others: Arsenic Cisapride Methadone Organophosphates Vasopressin |
|
Antipsychotics (chlorpromazine, droperidol, haloperidol, ziprasidone) |
Serotonin Augmentation. Serotonin syndrome, or serotonin hyperactivity syndrome, usually results when two or more serotonergic medications are combined, although it may occur with therapeutic doses or overdoses of a single serotonergic agent. It is thought to be mediated by excessive stimulation of serotonin 5-HT2A and 5-HT1A receptors.
The syndrome has a spectrum of severity from mild serotonin excess to life-threatening toxicity. The clinical diagnostic criteria include autonomic excitation (tachycardia, hypertension, diarrhea, diaphoresis), altered mental status, and increased muscle tone (myoclonus, tremor, hyperreflexia).35 There are no laboratory tests that can be used to confirm the diagnosis of serotonin syndrome.
A large number of drugs and drug interactions have been associated with serotonin syndrome, as many drugs alter serotonin transmission as a minor or major pharmacologic action.31 Increased serotonergic activity may be caused by a number of mechanisms, including direct serotonin agonism, increased synthesis, increased release, decreased breakdown, inhibition of re-uptake, and increased serotonergic tone.35 Table 5 summarizes drugs associated with serotonin excess.
Table 5: Selected Drugs that Increase Serotonergic Activity
|
Antidepressants (trazodone, venlafaxine, mirtazapine) |
MAOIs (phenelzine, moclobemide, clorgyline, isocarboxazid)36 |
|
Cocaine, amphetamines37 |
Meperidine38 |
|
Dextromethorphan39 |
St. John's wort (hyperforin)36 |
|
L-tryptophan |
SSRIs (fluoxetine, citalopram, paroxetine, fluvoxamine, sertraline) |
|
Linezolid (weak MAOI)37 |
Pentazocine38 |
|
Lithium |
Triptans39 |
|
LSD |
Tramadol40 |
Miscellaneous Interactions
Phosphodiesterase 5 (PDE5) inhibitors,37,38 such as sildenafil, tadalafil, and vardenafil, are prescribed to treat erectile dysfunction and pulmonary hypertension and are well known to interact with organic nitrates, producing significant hypotension.41 This is an example of a pharmacodynamic drug interaction, as the hypotension is due to a similar mechanism of action of the two medications. Nitrates increase the production of cyclic guanosine monophosphate (cGMP), resulting in vascular smooth muscle relaxation, while PDE5 inhibitors inhibit the breakdown of cGMP by the enzyme phosphodiesterase. This is a potentially common drug interaction because there is significant overlap in the risk factors for erectile dysfunction and the risk factors for which a patient may receive nitrates, such as angina and congestive heart failure.
Current American College of Cardiology and American Heart Association recommendations are to avoid administration of nitrates to patients who have used tadalafil in the past 48 hours due to its longer half-life, and in the past 24 hours for the other PDE5 inhibitors. Similarly, PDE5 inhibitors should be avoided in patients who are treated chronically with nitrates.42
Some patients develop orthostatic hypotension when a PDE5 inhibitor is used in conjunction with an alpha-blocking agent such as doxazosin, tamsulosin, and terazosin (typically for hypertension or benign prostatic hypertrophy). Some studies suggest that this drug interaction is less significant if the patient has been on long-term alpha-blocker therapy.42 Hypotension, however, does not typically occur with the concomitant use of other classes of antihypertensive drugs (ACE inhibitors, angiotensin receptor blockers, beta-blockers, calcium channel blockers, and diuretics).42
Sildenafil is metabolized by CYP3A4, and, therefore, its adverse effects may be increased in patients who are prescribed other medications that are metabolized by this enzyme. Such medications include macrolide and imidazole antibiotics, HMG-CoA reductase inhibitors, and highly active antiretroviral therapy (HAART).43 Sildenafil also may cause a prolonged QT interval by blocking the rectifying K current and therefore delaying repolarization.44
Proton Pump Inhibitors (PPIs) and Clopidogrel.41 The use of clopidogrel combined with a PPI has been the subject of recent controversy with the concern for a drug reaction resulting in decreased efficacy of clopidogrel and the potential for worsened cardiovascular outcomes.45 This has resulted in product labeling changes and advisories from organizations including the U.S. Food and Drug Administration (FDA).
A consensus document was published in 2010 by an expert panel from the American College of Cardiology, the American Heart Association, and the American College of Gastroenterology that reviewed the literature on this drug interaction.46 The panel concluded that, although there is a potential interaction between omeprazole and clopidogrel that could decrease the efficacy of clopidogrel, this does not seem to translate to cardiovascular harm. The studies that suggested cardiovascular harm were all observational and retrospective studies. The only prospective trial, the COGENT trial, showed no demonstrable cardiovascular harm. In fact, it showed a demonstrable gastrointestinal (GI) protective benefit in the patients who were prescribed the combination of omeprazole plus clopidogrel.47 Patients taking clopidogrel therapy who are at low risk for GI complications may be prescribed H2 blockers instead of a PPI. However, patients at moderate to high GI risk can still be treated with a PPI.
Aspirin (ASA) and Ibuprofen. This interaction is important for those with coronary artery disease (CAD) who benefit from the full antiplatelet effect of the salicylates.45 It has been demonstrated that ibuprofen interferes with the antiplatelet activity of low-dose ASA when they are ingested concurrently. The mechanism by which this occurs may be through competitive inhibition of the acetylation site of cyclooxygenase (COX) in the platelet. Both ibuprofen (reversible inhibition) and ASA (irreversible inhibition) occupy nearby sites on COX, such that the presence of ibuprofen interferes with ASA binding. Once the ibuprofen releases from the binding site, COX will not be fully inhibited because some ASA will already have been excreted. The net effect is a decrease in the aspirin-mediated irreversible inhibition of thromboxane B2 (TXB2) production and, therefore, less inhibition of platelet aggregation.45
The clinical implication of the interference by ibuprofen on the anti-platelet effect of ASA is unclear. Acetaminophen does not appear to interfere with the antiplatelet effect of low-dose ASA. Therefore, it is safer to use acetaminophen or narcotic analgesics in patients who need the full protection of ASA. Otherwise, space the dosing between the NSAIDs and ASA by 8 hours.45
Food Drug Interactions
Interactions between foods and drugs can have a profound influence on the efficacy of drug therapy and adverse drug effects. Such interactions are common, and can range from minor to harmful or even fatal. It is challenging for the clinician to identify food-drug interactions because food consumption is not usually documented in the medical record. In addition, new drugs are reaching the market with ever-increasing speed, and less information is available about their adverse effects and interactions at the time of release. These difficulties are also compounded by genetic differences that determine the susceptibility of individual patients. Some of the more important food-drug interactions are discussed below.
Monoamine oxidase (MAO) is a mitochondrial enzyme that is found in nerve terminals, the liver, intestinal mucosa, and other organs. It regulates the metabolic degradation of catecholamines and serotonin in the CNS or peripheral tissues, and, therefore, monoamine oxidase inhibitors (MAOI) have been used therapeutically to treat depression and Parkinson's disease. However, this mechanism of action has resulted in several important drug-drug and food-drug interactions with MAOI.
An important food-drug interaction occurs when an MAOI is combined with foods or beverages containing the amino acid tyramine, an indirectly acting sympathomimetic agent. When the metabolism of tyramine is inhibited by an MAOI, a significant release of norepinephrine occurs, resulting in marked hypertension, hyperthermia, cardiac arrhythmias, and cerebral hemorrhage. Tyramine is found in a number of foods, including chocolate and a variety of aged, fermented, overripe, pickled, or yeast-containing foods and beverages such as beer, wine, cheeses, avocados, and some processed meats.
Grapefruit juice is responsible for another important food-drug interaction. Grapefruit juice contains flavonoids (naringin and naringenin) and furanocoumarin phenylpropanoids (bergamottin and 6', 7'-dihydroxybergamottin), which inhibit CYP3A4 in the intestine and liver.48 This results in reduced metabolism of drugs that are eliminated by this isoenzyme. Bioavailability of these drugs may increase by 200%, leading to adverse drug effects.48
Medications affected by grapefruit juice include calcium channel blockers such as verapamil and the dihydropyridines (felodipine, nifedipine, nimodipine, nisoldipine, and nitrendipine), as well as the benzodiazepines (midazolam, triazolam). Also affected are the HMG-CoA reductase inhibitors (lovastatin and simvastatin more than atorvastatin), amiodarone, buspirone, cyclosporine, terfenadine, and quinine.2,4,49
Patients should avoid drinking grapefruit juice for two hours before and four hours after taking drugs in these categories. For extended-release preparations, the patient should wait until 6 hours have passed before drinking grapefruit juice.
Licorice has several important food-drug interactions. Licorice contains a saponin glycoside called glycyrrhizin, which inhibits 11-beta-hydroxysteroid dehydrogenase, the enzyme that converts cortisol to cortisone. Chronic ingestion of large amounts of licorice results in pseudohypoaldosteronism, with hypokalemia, muscle weakness, sodium and water retention, hypertension, and cardiac arrhythmias. Thus, licorice can interfere with the effectiveness of antihypertensive medications and worsen the hypokalemia that is associated with certain diuretics such as bumetanide, chlorothiazide, chlorthalidone, ethacrynic acid, furosemide, hydrochlorothiazide, metolazone, spironolactone, and torsemide. In addition, hypokalemia worsens the toxicity of digoxin. Licorice also decreases the effectiveness of warfarin and increases the risk of side effects for patients taking corticosteroid or estrogen therapy.50
Drug and Ethanol Interactions
Ethanol is known to cause a number of drug interactions, many of which may be severe or life-threatening.
A significant interaction occurs when ethanol is consumed with cocaine, resulting in the formation of an active metabolite known as cocaethylene. The half-life of cocaethylene is much longer than that of cocaine, resulting in prolonged toxicity. The metabolism of cocaine is inhibited, also prolonging and enhancing the effects of the parent compound.51
Other drugs interact with ethanol by inhibiting the enzyme acetaldehyde dehydrogenase. Normally, ethanol is metabolized to acetaldehyde by alcohol dehydrogenase and, subsequently, acetaldehyde is metabolized to acetic acid by aldehyde dehydrogenase. However, the inhibition of aldehyde dehydrogenase by another drug leads to the accumulation of acetaldehyde when ethanol is also consumed. This is the mechanism behind the disulfiram reaction, resulting in nausea, flushing, headache, and palpitations. Drugs known to cause this disulfiram-like reaction include certain cephalosporins, chloramphenicol, chlorpropamide, disulfiram, griseofulvin, metronidazole, and nitrofurantoin.52
A reaction also occurs when combining ethanol and tacrolimus.53 A local skin reaction of flushing and irritation has been reported at the site of topical tacrolimus application when ethanol is also consumed.54
Other notable ethanol-drug interactions include enhanced antiplatelet effect with aspirin; increased incidence of hepatitis with isoniazid; increased metabolism of methadone; increased hypoglycemic effect of oral hypoglycemics; increased metabolism of phenytoin; increased blood ethanol concentration with cimetidine and ranitidine; increased vasodilation with vasodilators; and increased metabolism of warfarin.
Finally, ethanol is a central nervous system depressant, potentiating the effects of other sedating drugs such as antihistamines, antidepressants, antipsychotics, barbiturates, gamma-hydroxybutyrate, marijuana, muscle relaxants, opioids, and any other sedative-hypnotic agent or central nervous system depressant.
Drugs and Dietary Supplement Interactions
More than 50% of Americans take dietary supplements on a daily basis. Supplements include vitamins, minerals, amino acids, herbs, and botanicals. A memory aid to help remember a group of the most common supplements involved in drug interactions is those beginning with the letter "g": ginger, garlic, ginkgo, and grapefruit.55
Table 6: Drug Interactions with Common Dietary Supplements
|
Supplement Name |
Interaction |
|
Caffeine |
Found in many beverages Potentiates the effects of amphetamines and other sympathomimetics |
|
Dong quai36 |
Has warfarin derivatives: Risk of bleeding31 |
|
Ephedra55 |
Potentiates effects of caffeine |
|
Feverfew |
Associated with bleeding when used with warfarin |
|
Garlic |
Inhibits platelet aggregation: Increased risk of bleeding with warfarin |
|
Ginger |
Thromboxane synthetase inhibitor and may also decrease platelet aggregation: Increased risk of bleeding |
|
Ginkgo biloba56 |
Decreases activity of valproic acid and carbamazepine Potent inhibitor of platelet activating factor: Risk of bleeding with warfarin and NSAIDs |
|
Ginseng55 |
Can potentiate bleeding when used with warfarin and NSAIDs Potentiates MAOI |
|
St. John's wort56 |
Decreased anticancer drug concentrations (irinotecan, imatinib) Decreased antiretroviral concentration (indinavir, nevirapine) Decreased cyclosporine concentrations Decreased OCP activity P450 inducer; lowers levels of many medicines (indinavir, cyclosporine, digoxin, warfarin)31 Serotonergic properties may cause serotonin syndrome with SSRI |
|
Vitamin E |
Warfarin potentiation |
Table 6 summarizes commonly used supplements in the United States and their reported interactions.50
Physician and Patient Education
Special attention should be paid when prescribing medications in the following settings:
When the therapeutic effect of a drug is harmful in excess (or when it is insufficient) and the therapeutic margin is narrow, such as sulfonylureas, anticoagulants, CNS depressants, digoxin, and cytotoxic drugs;2,11
When the drug produces altered receptor sensitivity in the autonomic nervous system, such as monoamine oxidase inhibitors, tricyclic antidepressants, antipsychotics, and cardiovascular medications;
When over-the-counter medications, dietary supplements, and herbal remedies are used and self-prescription occurs;
When several practitioners are providing care, especially when the medical record is not integrated and accessible to all;
When combination medicines are prescribed by trade name.2
Patients should be educated about drug interactions and instructed to seek medical evaluation if symptoms occur.11 Some useful patient tips provided by the Institute for Safe Medical Practices include:
Read labels;
Know drug warnings;
Keep drugs in original containers;
Ask your doctor about drug, food, and dietary supplement interactions;
Ask your pharmacist before taking over-the-counter medications if you are taking a prescription medicine;
Use one pharmacy for all your medicines;
Inform all your doctors about all your medicines, including supplements;
Keep a list of all your medicines, including supplements;
Don't save medicines for future use;
Don't share medicines;
Don't double doses of medicines.
Physicians can decrease the risk of drug interactions by selecting medication regimens that optimize therapeutic benefit while minimizing the risk of adverse drug events. Medications that are not essential should be eliminated, especially in high-risk patients who are taking multiple drugs. Physicians should keep informed of important drug interactions and be able to recognize the clinical presentation of drug interactions, which may mimic other disease states. It is important to use available resources such as Internet sites and computerized databases to help screen for drug interactions.
Many hospitals and pharmacies utilize clinical decision software. In at least in one study, these software programs did not perform well, but, nevertheless, they are useful tools, as they alert clinicians about potential drug interactions.57
Some pharmacy schools have increased the education of pharmacists about drug interactions, since pharmacists are a source of information for many physicians.58 A study in the medical intensive care unit showed that having a clinical pharmacist during rounds decreased potential drug interactions by 65% and decreased length of stay. Mortality was not affected.59
Online resources are also helpful, especially when dealing with rapidly changing or dangerous drugs, such as in oncology and HIV. Finally, report all drug interactions to MedWatch or to the local Poison Control Center.60 These are the best ways to identify and track drug interactions that may affect patient safety.
Conclusions
Drug interactions occur when the effects of a drug are modified by the concomitant administration of another substance, most commonly another prescription medication. However, serious drug interactions also occur with over-the-counter medications, foods, vitamins, dietary supplements, herbal products, alcohol, and illicit drugs. These adverse drug events are a common cause of morbidity and mortality, resulting in billions of dollars annually in additional health care costs.
The risk of drug interactions increases significantly with the number of medications used. Patients at increased risk of drug interactions include those taking multiple medications, especially the chronically ill, elderly, critically ill patients with organ compromise, children with special health care needs, and patients who consume over-the-counter, dietary, and herbal preparations.
Physicians need to educate themselves and their patients on the most common and the most deadly drug interactions. The use of computer software, pharmacists, online resources, and the Poison Control Center are all options that help reduce the probability of serious drug interactions.
References
1. Qato DM, Alexander GC, Conti RM, et al. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA 2008;300:2867-2878.
2. Richens A. Drug interactions and lethal drug combinations. J Clin Pathol Suppl (R Coll Pathol) 1975;9:94-98.
3. Hanlon JT, Fillenbaum GG, Ruby CM, et al. Epidemiology of over-the-counter drug use in community dwelling elderly: United States perspective. Drugs Aging 2001;18:123-131.
4. Paauw D. Commonly overlooked drug interactions. Emergency Medicine http://www.emedmag.com/html/pre/fea/features/031501.asp. Accessed June 28, 2011.
5. Smithburger PL, Kane-Gill SL, Seybert AL. Drug-drug interactions in cardiac and cardiothoracic intensive care units: An analysis of patients in an academic medical centre in the US. Drug Saf 2010;33: 879-888.
6. Goldberg RM, Mabee J, Chan L, et al. Drug-drug and drug-disease interactions in the ED: Analysis of a high-risk population. Am J Emerg Med 1996;14:447-450.
7. Becker ML, Kallewaard M, Caspers PW, et al. Hospitalisations and emergency department visits due to drug-drug interactions: A literature review. Pharmacoepidemiol Drug Saf 2007;16:641-651.
8. Bertoli R, Bissig M, Caronzolo D, et al. Assessment of potential drug-drug interactions at hospital discharge. Swiss Med Wkly 2010;140:w13043.
9. Unintentional poisoning deaths United States, 1999-2004. MMWR Morb Mortal Wkly Rep 2007;56:93-96.
10. Avorn J. Medication use and the elderly: Current status and opportunities. Health Aff (Millwood) 1995;14:276-286.
11. Chadwick B, Waller D, JG E. Potentially hazardous drug interactions with psychotropics. Advances in Psychiatric Treatment 2005;11:440-449.
12. Nobili A, Pasina L, Tettamanti M, et al. Potentially severe drug interactions in elderly outpatients: Results of an observational study of an administrative prescription database. J Clin Pharm Ther 2009;34:377-386.
13. Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. Lancet 2007;370: 185-191.
14. Sierra P, Castillo J, Gomez M, et al. [Potential and real drug interactions in critical care patients]. Rev Esp Anestesiol Reanim 1997;44:383-387.
15. Linnoila M, Mattila MJ, Kitchell BS. Drug interactions with alcohol. Drugs 1979;18:299-311.
16. Guengerich FP. Cytochrome p450 and chemical toxicology. Chem Res Toxicol 2008;21:70-83.
17. Norton JC, Ludwig AM. Medical treatment of psychiatric patients: Possible polypharmacy problems. Hosp Community Psychiatry 1982;33:305-307.
18. Shakeri-Nejad K, Stahlmann R. Drug interactions during therapy with three major groups of antimicrobial agents. Expert Opin Pharmacother 2006;7: 639-651.
19. Yeung CK, Fujioka Y, Hachad H, et al. Are circulating metabolites important in drug-drug interactions? Quantitative analysis of risk prediction and inhibitory potency. Clin Pharmacol Ther 2011;89:105-113.
20. Hirsh J, Fuster V, Ansell J, et al. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 2003;107:1692-1711.
21. Garcia-Caballos M, Ramos-Diaz F, Jimenez-Moleon JJ, et al. Drug-related problems in older people after hospital discharge and interventions to reduce them. Age Ageing 2010;39:430-438.
22. Juurlink DN. Drug interactions with warfarin: What clinicians need to know. CMAJ 2007;177:369-371.
23. Tadros R, Shakib S. Warfarin indications, risks and drug interactions. Aust Fam Physician 2010;39:476-479.
24. Chan TY. Life-threatening retroperitoneal bleeding due to warfarin-drug interactions. Pharmacoepidemiol Drug Saf 2009;18:420-422.
25. Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: Recent data and ideas. Stroke 2005;36: 1588-1593.
26. Kurnik D, Loebstein R, Farfel Z, et al. Complex drug-drug-disease interactions between amiodarone, warfarin, and the thyroid gland. Medicine (Baltimore) 2004;83:107-113.
27. Hylek EM, Heiman H, Skates SJ, et al. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 1998;279:657-662.
28. Smithburger PL, Seybert AL, Armahizer MJ, et al. QT prolongation in the intensive care unit: Commonly used medications and the impact of drug-drug interactions. Expert Opin Drug Saf 2010;9:699-712.
29. Kao LW, Furbee RB. Drug-induced q-T prolongation. Med Clin North Am 2005;89:1125-1144, x.
30. Prybys KM. Deadly drug interactions in emergency medicine. Emerg Med Clin North Am 2004;22:845-863.
31. Schellander R, Donnerer J. Antidepressants: Clinically relevant drug interactions to be considered. Pharmacology 2010;86:203-215.
32. Koponen H, Alaraisanen A, Saari K, et al. Schizophrenia and sudden cardiac death: A review. Nord J Psychiatry 2008;62: 342-345.
33. Saari TI, Olkkola KT. Azole antimycotics and drug interactions in the perioperative period. Curr Opin Anaesthesiol 2010;23:441-448.
34. Goto CS, Feng S-Y, Wiebe RA. How to prevent harmful drug interactions. Emergency Medicine 2008;40:25.
35. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005;352: 1112-1120.
36. Borrelli F, Izzo AA. Herb-drug interactions with St John's wort (Hypericum perforatum): An update on clinical observations. AAPS J 2009;11:710-727.
37. Clark DB, Andrus MR, Byrd DC. Drug interactions between linezolid and selective serotonin reuptake inhibitors: Case report involving sertraline and review of the literature. Pharmacotherapy 2006;26:269-276.
38. Hansen TE, Dieter K, Keepers GA. Interaction of fluoxetine and pentazocine. Am J Psychiatry 1990;147:949-950.
39. Shapiro RE, Tepper SJ. The serotonin syndrome, triptans, and the potential for drug-drug interactions. Headache 2007;47:266-269.
40. Hersh EV, Pinto A, Moore PA. Adverse drug interactions involving common prescription and over-the-counter analgesic agents. Clin Ther 2007;29 Suppl: 2477-2497.
41. Schwartz BG, Kloner RA. Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension. Circulation 2010;122:88-95.
42. Kloner RA. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: Focus on alpha-blocker interactions. Am J Cardiol 2005;96: 42M-46M.
43. Hall MC, Ahmad S. Interaction between sildenafil and HIV-1 combination therapy. Lancet 1999;353:2071-2072.
44. Geelen P, Drolet B, Rail J, et al. Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. Circulation 2000;102:275-277.
45. Mackenzie IS, Coughtrie MW, MacDonald TM, et al. Antiplatelet drug interactions. J Intern Med 2010;268:516-529.
46. Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: A focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation 2010;122:2619-2633.
47. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010;363:1909-1917.
48. Fuhr U. Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance. Drug Saf 1998;18: 251-272.
49. Seden K, Dickinson L, Khoo S, et al. Grapefruit-drug interactions. Drugs 2010;70:2373-2407.
50. Miller LG. Herbal medicinals: Selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med 1998;158(20):2200-2211.
51. Parker RB, Williams CL, Laizure SC, et al. Effects of ethanol and cocaethylene on cocaine pharmacokinetics in conscious dogs. Drug Metab Dispos 1996;24: 850-853.
52. Saxe TG. Drug-alcohol interactions. Am Fam Physician 1986;33:159-162.
53. Jang GR, Harris RZ. Drug interactions involving ethanol and alcoholic beverages. Expert Opin Drug Metab Toxicol 2007;3:719-731.
54. Knight AK, Boxer M, Chandler MJ. Alcohol-induced rash caused by topical tacrolimus. Ann Allergy Asthma Immunol 2005;95:291-292.
55. Ulbricht C, Chao W, Costa D, et al. Clinical evidence of herb-drug interactions: A systematic review by the natural standard research collaboration. Curr Drug Metab 2008;9:1063-1120.
56. Abad MJ, Bedoya LM, Bermejo P. An update on drug interactions with the herbal medicine Ginkgo biloba. Curr Drug Metab 2010;11:171-181.
57. Saverno KR, Hines LE, Warholak TL, et al. Ability of pharmacy clinical decision-support software to alert users about clinically important drug-drug interactions. J Am Med Inform Assoc 2011;18:32-37.
58. Ko Y, Malone DC, Skrepnek GH, et al. Prescribers' knowledge of and sources of information for potential drug-drug interactions: A postal survey of US prescribers. Drug Saf 2008;31:525-536.
59. Rivkin A, Yin H. Evaluation of the role of the critical care pharmacist in identifying and avoiding or minimizing significant drug-drug interactions in medical intensive care patients. J Crit Care 2011;26:104 e101-106.
60. Holstege CP, Mitchell K, Barlotta K, et al. Toxicity and drug interactions associated with herbal products: Ephedra and St. John's Wort. Med Clin North Am 2005;89:1225-1257.
My emergency department (ED) has had an electronic medical record for the past two years. Part of that record includes a medication list that is created from past encounters and updated by the triage nurse. Because it is electronic and prints out nicely in the triage summary, it has the appearance of truth. My experience with the list is likely similar to some of yours: Patients are often taking medications not on the list and are not currently taking those that are.Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.